HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $130

Benzinga Newsdesk www.benzinga.com Negative 46.9%

Neg 46.9% Neu 0% Pos 0%

HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $140 to $130.